Myasthenia Gravis Exacerbation Following Second Dose of mRNA-1273 Vaccine
DOI:
https://doi.org/10.17161/rrnmf.v2i2.15342Keywords:
Myasthania Gravis Exacerbation, m-RNA 1273, COVID 19 VaccinationsAbstract
NA
Metrics
Downloads
References
Guidon, A.C. and A.A. Amato, COVID-19 and neuromuscular disorders. Neurology,
94(22): p. 959-969. doi: 10.1212/WNL.0000000000009566
Paliwal, V.K., et al., Neuromuscular presentations in patients with COVID-19. Neurol Sci,
41(11): p. 3039-3056. doi: 10.1007/s10072-020-04708-8
Muppidi, S., et al., COVID-19-associated risks and effects in myasthenia gravis (CARE MG). Lancet Neurol, 2020. 19(12): p. 970-971. doi: 10.1016/S1474-4422(20)30413-0
Baden, L.R., et al., Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 2021. 384(5): p. 403-416. doi: 10.1056/NEJMoa2035389
Anderson, E.J., et al., Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med, 2020. 383(25): p. 2427-2438. doi: 10.1056/NEJMoa2028436
Repajic, M., et al., Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy. Brain Behav Immun Health, 2021. 13: p. 100217. doi: 10.1016/j.bbih.2021.100217
Supplemental References :
US Food and Drug Administration (2020) Pfizer-BioNTech COVID-19 vaccine emergency use authorization review memorandum. https://www.fda.gov/media/144416/download. Accessed 15 Jan 2021
US Food and Drug Administration (2020) Moderna COVID-19 vaccine emergency use authorization review memorandum. https://www.fda.gov/media/144673/download. Accessed 15 Jan 2021
US Food and Drug Administration (2021) Janssen COVID-19 Vaccine EUA Letter of Authorization (fda.gov)
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Urvi G Desai MBBS, MS, MD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
